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when maximal pharmacologic support or the use of
intra-aortic balloon pump counterpulsation is ineffec-
tive.4 A variety of left ventricular assist devices have
been applied for the treatment of acute heart failure.
These devices offer hope of the improvement of sur-
vival for patients with postcardiotomy cardiogenic
shock.5-8 However, the application of these devices usu-
ally requires a surgical procedure and involves signifi-
cant morbidity.9-11
The intra-aortic cannula pump (IACP) is a catheter
pump (Hemodynamics LTD, Upper Yoqneam, Israel)
designed to support the failing heart by expelling blood
in a pulsatile flow pattern from the left ventricle into the
ascending aorta. It can be introduced by various
approaches.
The aim of this study was to analyze the hemody-
namic effects of this new intracardiac support system in
a model of acute heart failure.
C ardiogenic shock remains 1 of the leading causes ofdeath in spite of major progression in cardiac
surgery and cardiology.1-3 Ventricular assist devices are
generally used for the treatment of severe heart failure
Objective: The intra-aortic cannula pump is a catheter pump designed to
support the acutely failing heart. It expels blood from the left ventricle
into the ascending aorta in a pulsatile flow pattern. The aim of the study
was to analyze the hemodynamic performance of this new intracardiac
support system in acute heart failure. Methods: A 24F cannula was stud-
ied in a series of 16 sheep. Hemodynamic changes were assessed in the
nonfailing, the moderately failing, and the severely failing heart. Heart
failure was induced by an injection of microspheres into the left anteri-
or descending coronary artery. The cannula was inserted through the
aortic arch and introduced through the aortic valve into the left ventri-
cle. Results: Cannula insertion was feasible in all animals. Flow through
the intra-aortic cannula flow was increased to a maximum of 3 L/min.
No hemodynamic changes were observed in the nonfailing heart. A sig-
nificant increase in cardiac output was observed in the moderately and
severely reduced left ventricle (2.67 ± 0.7 L to 3.51 ± 0.83 L; P = .001;
and 1.18 ± 0.77 L to 2.43 ± 0.44 L; P = .001, respectively). A drop in left
atrial pressure was achieved in moderate and severe heart failure (14.1
± 5.93 mm Hg to 9.71 ± 2.63 mm Hg; P = .0001; and 23 ± 7.16 mm Hg
to 11.2 ± 2.55 mm Hg; P = 0.0001, respectively). Systolic and diastolic
systemic blood pressures increased in the severely failing heart (57.3 ±
12.8 mm Hg to 75.4 ± 11.2 mm Hg; P = .0001; and 35.6 ± 8.2 mm Hg to
60 ± 14.3 mm Hg; P = .0006, respectively). Conclusions: Hemodynamic
data demonstrate the beneficial effects of the intra-aortic cannula pump
in moderate and severe heart failure. The intra-aortic cannula pump
represents a new modality for the treatment of acute heart failure.
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Material and methods
Sixteen sheep, weighing 45 to 60 kg, were used in this
study. All animals received humane care in compliance with
the “Guide for the Care and Use of Laboratory Animals” pre-
pared by the Institute of Laboratory Animal Resources,
National Research Council, and published by the National
Academy Press, revised 1996.
Anesthesia. After a 36-hour food fasting period, all ani-
mals received premedication with 0.2 mg/kg body weight
intramuscular atropine. General anesthesia was induced with
0.20 mg/kg intramuscular xylazine and 10 mg/kg intramus-
cular ketamine. To facilitate endotracheal intubation, a non-
depolarizing muscle relaxant, intravenous atracurium 0.5
mg/kg, was used. Positive pressure ventilation (Harvard
Apparatus Co, S Natick, Mass) was started (oxygen/room air
mixture 1:1; halothane, 0.5% to 1.0%). Anesthesia was main-
tained with intravenous administration of fentanyl (0.02
mg/kg) and atracurium (0.5 mg/kg). Continuous electrocar-
diography was used for heart rate and rhythm recording.
Operative procedure and experimental protocol. After
left thoracotomy was performed, the pericardium was opened
and suspended. To prevent ventricular arrhythmia during
manipulation of the heart, 100 mg of lidocaine HCl was given
intravenously with the opening of the pericardial sac. A con-
tinuous infusion at a dose of 1 mg/kg per hour was started
thereafter. Baseline activated clotting time was recorded, and
heparin was administrated intravenously at a dose of 300
IU/kg. Activated clotting time was maintained above 480 sec-
onds throughout the procedure. Fluid manometer lines were
inserted to the left atrium and femoral artery for hemody-
namic measurements. Simultaneous monitoring was per-
formed with an 8-channel recorder (Kipp & Zonen, Delft,
The Netherlands). Continuous cardiac output monitoring was
performed with an ultrasonic flow probe (Transonic Systems,
Ithaca, NY) placed around the main pulmonary artery.
The IACP support system consists of a pulsatile pump and
a disposable cannula-valve unit, which expels blood from the
left ventricle into the ascending aorta (Fig 1). The device
comprises (Fig 2) an electrohydraulic-driven piston that
forces fluid into the disposable head, triggered by the electro-
cardiogram. The fluid displaces a polyurethane membrane,
enabling a pulsatile blood flow through the cannula with a
valve mechanism.12 During the unloading phase (Fig 2, A),
the blood is pumped from the tip of the catheter, through a 1-
way valve, while the side holes in the aortic segment of the
catheter are kept closed by another, opposite, 1-way valve. In
the expelling phase (Fig 2, B), the tip valve is in the closed
position, which expels blood only from the aortic side holes.
After surgical preparation of the aortic arch, the IACP was
inserted, and the tip of the cannula was advanced to the left
ventricular cavity. Tip positioning was verified by pressure
measurement. IACP flow was gradually increased until max-
imal flow of 3.0 L was achieved and was recorded in differ-
ent flow rates.
The induction of heart failure was performed by emboliza-
tion13 of beads (Bangs Laboratories Inc, Fishers, Ind) into the
left anterior descending coronary artery in repeated doses of
0.2 mL. Heart failure was defined as moderate when cardiac
output (CO) declined in increments of 25% to 50% related to
baseline and as severe when the decrease in CO exceeded 50%.
Hemodynamic variables were recorded at baseline condi-
tion and during moderate and severe heart failure. All mea-
surements were recorded with and without IACP support.
Statistics. The results are presented as mean ± SE. We cre-
ated general linear models by the method of least squares to
perform analysis of variance and covariance. We account for
the fact that each of these 16 animals was studied at each of
the 3 levels of heart failure by including animal designation
in the linear model. For comparing a variable between differ-
ent heart failure degrees, we computed the adjusted least
squares mean of the variable at each heart failure degree. We
computed the SE of the least square means. We used t tests
for comparing between the LSM. Computations were per-
formed by SAS 6.12 software (SAS/STAT User’s guide
Version 6; SAS Institute Inc, Cary, NC). 
Results
The hemodynamic condition of all animals was sta-
ble during the baseline phase. Induction of moderate
and severe heart was successfully accomplished. All
animals survived the study protocol. No inotropic sup-
port was given during the entire procedure. In the pre-
liminary series, we used a tube graft sutured to the aor-
Fig 1. The IACP is a catheter pump. It expels blood from the
left ventricle into the ascending aorta in a pulsatile flow pattern.
926 Sharony et al The Journal of Thoracic and
Cardiovascular Surgery
November 1999
tic side and inserted the cannula through it. Later, we
found this method unnecessary because of the reason-
able size of the cannula as compared with the aorta and
introduced it in a direct fashion. Passing the device
through the aortic valve was feasible in all cases.
However, in some cases, a slight pressure on the aortic
root was required to facilitate the insertion. No damage
to the aortic valve leaflets was observed.
Left ventricular and aortic pressures were measured
during catheter insertion and after correct positioning
in the left ventricle with no transvalvular gradient. The
catheter did not cause any aortic incompetence as mea-
sured by left ventricular end-diastolic pressures before
and after its positioning. During catheter operation, left
ventricular end-diastolic negative pressures were mea-
sured subsequent to the device pumping mechanism.
Blood loss was minimal without the need for blood
transfusions. Table I summarizes the hemodynamic
variables at baseline condition and after induction of
heart failure.
Once moderate heart failure was induced; a signifi-
cant decrease in CO, diastolic arterial blood pressure
(ABP) as well as an increase in left atrial pressure
(LAP) was noted (26%, P < .001; 21%, P < .001; 33%,
P < .001, respectively). During severe heart failure CO
further declined in 66% related to baseline (P < .001).
A reduction in systolic and diastolic ABP in 40% (P <
.001) and 52% (P < .001), respectively, was observed,
with a concomitant 130% increase in LAP (P < .001).
During IACP activation, a significant increase in CO
was observed both in moderate and severe heart fail-
ure. Fig 3 demonstrates a linear model of the increase
in CO related to IACP flow. Maximal IACP assist up
to 236% ± 69% was achieved in severe heart failure
(P < .001).
Systolic and diastolic ABP increased significantly by
Fig 2. Schematic cross-section of the IACP. A, Unloading phase. B, Expelling phase. The IACP consists of a pul-
satile pump and a disposable cannula-valve unit. It comprises an electrohydraulic driven piston that forces fluid
into the head (triggered by electrocardiogram [ECG]) and displaces a polyurethane membrane, enabling a pul-
satile blood flow through the cannula with a valve mechanism.
Table I. Hemodynamic variables at baseline condition
and after induction of heart failure
Moderate Severe 
Baseline heart failure heart failure
CO (L/min) 3.5 ± 0.8 2.6 ± 0.4* 1.2 ± 0.4*
Systolic ABP 96.1 ± 24.8 84 ± 24.4 57.3 ± 14.6*
(mm Hg)
Diastolic ABP 73.3 ± 25.6 58.2 ± 23.6* 35.1 ± 3.6*
(mm Hg)
LAP (mm Hg) 10.6 ± 5.2 14.1 ± 6* 23.2 ± 7.6*
All values are presented as mean ± SD.
*P < .001.
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the IACP only in the severely failing heart and in flow
rates over 1.5 L/min (Fig 4) to a maximum of 51% ±
15% and 73% ± 11%, respectively (P < .001).
IACP activation caused a significant decrease in left
atrial pressure both in moderate and severe heart failure
(Fig 5).
Discussion
Heart failure, whether acute or chronic, is associated
with poor prognosis and limited life expectancy.14,15 In
severe cases of acute heart failure, the mortality rate
can exceed 85%.16 The immediate treatment modalities
available to patients with cardiogenic shock are limited.
Once medical therapy and intra-aortic balloon pumping
are found to be insufficient, ventricular assist devices
are usually necessary. The two major indications for
the application of ventricular assist devices are postcar-
diotomy cardiogenic shock and acute myocardial
infarction.
A myocardial infarction model with intracoronary
injection of microspheres was chosen for cardiac failure
induction, because of its simplicity and the controlled,
staged failure that it achieves. In this study, we used the
IACP, a catheter pump that can deliver pulsatile blood
flow at a rate exceeding 3 L/min. The application of the
IACP rapidly unloads the left ventricle, as evidenced by
a significant reduction in left atrial pressure. The IACP
increases diastolic arterial blood pressure, thus aug-
Fig 4. Linear model presents the change in diastolic ABP that is related to IACP flow at baseline, moderate, and
severe heart failure. Diastolic ABP increased significantly (P < .001) only in the severely failing heart and in flow
rates over 1.5 L/min. Data are shown as the mean ± SEM.
Fig 3. Linear model presents the change in CO that is related to IACP flow at baseline, moderate, and severe heart
failure. A significant increase in CO was observed both in moderate and severe heart failure (P < .01). Data are
shown as the mean ± the SE of the least squares mean.
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menting coronary perfusion. Furthermore, use of the
IACP may contribute to myocardial recovery by reduc-
ing ventricular wall tension and consequently decreas-
ing the oxygen requirement.17,18 These favorable effects
may lead to infarct size limitation19 and protect against
further ischemia by minimizing the unfavorable redis-
tribution of coronary blood flow.20
The IACP effect was maximal during severe heart fail-
ure because of the relatively high contribution of the
device to CO. Although the hemodynamic benefits of
transaortic flow pumping are well established,21 the use
of a pulsatile catheter pump in this application is novel.
Despite the fact that pulsatile versus nonpulsatile perfu-
sion is a topic of continuing controversy, it is acknowl-
edged that the benefits of pulsatile perfusion are mainly
manifested in high-risk patients.22 The advantage of pul-
sating flow is its similarity to normal physiologic condi-
tions. As such, it ameliorates whole body inflammatory
response and maintains normal organ function, produc-
ing flow and mean intravascular pressure rates that are
lower than those produced with nonpulsatile flow.23,24
In preliminary safety studies, no evidence of hemol-
ysis was observed that was associated with the opera-
tion of this device. The IACP can be inserted directly
into the aorta or its major tributaries without the need
to anastomose a tube graft, rendering the procedure less
traumatic. Correct tip positioning is accomplished by
pressure monitoring, thus eliminating the need for flu-
oroscopy or echocardiography.
This type of cannula produced a maximum of 3
L/min, a flow that could not be sufficient to permit a
total substitution of a failing heart. The device described
is not designed as a total artificial left heart. The select-
ed 24F cannula is an optimization between medium-
sized catheter diameter and subsequent flow capacity
limitation but minimizes surgical complexities. To
achieve a higher flow, a larger cannula can be intro-
duced through the same approach or by apical insertion.
The IACP, designed as a short-term circulatory sup-
port system, is intended mainly as a bridge to myocar-
dial recovery. This system can be easily replaced by
another device to provide long-term assistance, in the
event that such myocardial recovery does not occur.
In this study, we demonstrated the beneficial hemo-
dynamic effect of a pulsatile 24F IACP cannula in an
animal model of cardiac failure as the result of myocar-
dial ischemia. Several limitations of this 24F catheter
pump were noted. Maximal flow is limited below the
native CO. It can be used as an assist and not as a sub-
stitute device. For further clinical use, a transfemoral
insertion will be attractive but will require minimiza-
tion of catheter diameter.
Additional studies are needed to investigate the appli-
cation of this new device in other failure conditions.
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